Business
Novo Slides as Amgen Fuels Obesity Drug Competition Fears - Bloomberg
Novo Nordisk A/S shares fell as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing field.
By: Bloomberg
- May 04 2024
- 0
- 0 Views
Novo Nordisk A/S shares fell as a US rivals comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing field.
The stock slid as much as 5.3… [+254 chars]